Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jian-Yu E

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Cancer Medicine|February 9, 2020
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancerXiang-Lin Tan, Jian-Yu E, Yong Lin, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
The Lancet. Oncology|July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Han Liang, Ziyu Li, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Cancer Medicine|February 9, 2020
Individual and joint effects of metformin and statins on mortality among patients with high-risk prostate cancerXiang-Lin Tan, Jian-Yu E, Yong Lin, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
The Lancet. Oncology|July 12, 2021
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Han Liang, Ziyu Li, et al.
Pageof 4